{"hands_on_practices": [{"introduction": "A fundamental component of any Statistical Analysis Plan (SAP) is the precise definition of the analysis populations. These definitions determine which subjects are included in the primary, secondary, and sensitivity analyses, directly impacting the study's conclusions. This exercise [@problem_id:5063608] provides hands-on practice in applying the strict, rule-based logic required to assign subjects to populations like the Intent-to-Treat (ITT) and Per-Protocol (PP), a critical skill for ensuring the integrity and reproducibility of a clinical trial.", "problem": "A translational Phase IIa trial in an inflammatory indication evaluates the effect of an investigational small molecule on a continuous biomarker measured at nominal Week $12$. The statistical analysis plan (SAP) prespecifies the primary estimand in the spirit of the International Council for Harmonisation (ICH) E9(R1) addendum: the population-level contrast is the difference in mean change from baseline at Week $12$ between active and placebo among all randomized patients, handling intercurrent events of early withdrawal, dosing interruption, and use of rescue medication via a treatment policy strategy. The SAP further prespecifies analysis populations as follows, to be used for primary, supportive, and sensitivity analyses:\n\n- Intent-to-treat (ITT): all randomized subjects.\n- Safety: all subjects receiving at least one dose of study drug.\n- Modified intent-to-treat (mITT): all subjects who receive at least one dose of study drug and have a non-missing baseline biomarker assessment.\n- Per-protocol (PP): all mITT subjects who meet all of these criteria: no major protocol deviations impacting the primary endpoint, no use of rescue medication prior to the end of the Week $12$ visit window, cumulative on-treatment exposure proportion $E \\geq 0.80$ up to the end of the Week $12$ window, and an observed Week $12$ biomarker measurement within the prespecified window.\n\nA database snapshot at database lock lists $14$ randomized subjects, denoted $S_{1},\\dots,S_{14}$. For each subject, the following attributes are recorded: received any dose, baseline biomarker availability, major protocol deviations impacting the primary endpoint, rescue medication use before the end of the Week $12$ window, exposure proportion $E$ (fraction of planned dosing days completed up to the end of the Week $12$ window), and whether the Week $12$ biomarker was observed within the window. The snapshot is:\n\n- $S_{1}$: received dose, baseline available, no major deviation, no rescue, $E=0.92$, Week $12$ observed.\n- $S_{2}$: received dose, baseline available, major deviation, no rescue, $E=0.97$, Week $12$ observed.\n- $S_{3}$: received dose, baseline available, no major deviation, rescue at Week $8$, $E=0.85$, Week $12$ observed.\n- $S_{4}$: received dose, baseline available, no major deviation, no rescue, prolonged interruption yields $E=0.76$, Week $12$ observed.\n- $S_{5}$: randomized, withdrew before first dose, baseline available, Week $12$ not observed.\n- $S_{6}$: received dose, baseline missing, no major deviation, no rescue, $E=0.88$, Week $12$ observed.\n- $S_{7}$: received dose, baseline available, no major deviation, no rescue, $E=0.83$, Week $12$ not observed.\n- $S_{8}$: received dose, baseline available, no major deviation, no rescue, $E=0.81$, Week $12$ observed.\n- $S_{9}$: received dose, baseline available, no major deviation, no rescue, $E=1.00$, Week $12$ observed.\n- $S_{10}$: received dose, baseline available, no major deviation, no rescue, $E=0.79$, Week $12$ observed.\n- $S_{11}$: received dose, baseline available, no major deviation, no rescue, $E=0.90$, Week $12$ observed.\n- $S_{12}$: received dose, baseline available, no major deviation, no rescue, $E=0.86$, Week $12$ observed.\n- $S_{13}$: received dose, baseline available, no major deviation, rescue at Week $11$, $E=0.95$, Week $12$ observed.\n- $S_{14}$: received dose, baseline available, major deviation, no rescue, $E=0.82$, Week $12$ observed.\n\nUsing only the definitions above and considering the primary estimandâ€™s treatment-policy handling of intercurrent events for the primary analysis, determine the number of subjects in the per-protocol (PP) population according to the SAP definition. Provide a single integer as your final answer. No rounding instruction is necessary because the answer is a count.", "solution": "The objective is to determine the number of subjects in the per-protocol (PP) population. The definition of the PP population begins with the modified intent-to-treat (mITT) population. Therefore, we must first identify the subjects who belong to the mITT population.\n\n**Step 1: Identify the Modified Intent-to-Treat (mITT) Population**\n\nThe statistical analysis plan (SAP) defines the mITT population as \"all subjects who receive at least one dose of study drug and have a non-missing baseline biomarker assessment.\" We will examine each of the $14$ randomized subjects, denoted $S_1$ through $S_{14}$, against these two criteria.\n\n-   Subject $S_5$: \"randomized, withdrew before first dose\". This subject fails the criterion of receiving at least one dose.\n-   Subject $S_6$: \"received dose, baseline missing\". This subject fails the criterion of having a non-missing baseline biomarker assessment.\n\nAll other $12$ subjects ($S_1, S_2, S_3, S_4, S_7, S_8, S_9, S_{10}, S_{11}, S_{12}, S_{13}, S_{14}$) received at least one dose and have an available baseline biomarker. Therefore, the mITT population consists of these $12$ subjects.\n\nThe set of mITT subjects is {$S_1, S_2, S_3, S_4, S_7, S_8, S_9, S_{10}, S_{11}, S_{12}, S_{13}, S_{14}$}.\n\n**Step 2: Apply Per-Protocol (PP) Criteria to the mITT Population**\n\nThe SAP defines the PP population as \"all mITT subjects who meet all of these criteria:\n1.  No major protocol deviations impacting the primary endpoint.\n2.  No use of rescue medication prior to the end of the Week $12$ visit window.\n3.  Cumulative on-treatment exposure proportion $E \\geq 0.80$ up to the end of the Week $12$ window.\n4.  An observed Week $12$ biomarker measurement within the prespecified window.\"\n\nWe will now evaluate each of the $12$ subjects in the mITT population against these four criteria. A subject must satisfy all four criteria to be included in the PP population.\n\n-   $S_1$: Meets all criteria. (1) No major deviation. (2) No rescue. (3) $E=0.92$, and $0.92 \\geq 0.80$. (4) Week $12$ observed. **Included in PP.**\n-   $S_2$: Fails criterion (1). The subject had a major deviation. **Excluded from PP.**\n-   $S_3$: Fails criterion (2). The subject used rescue medication at Week $8$, which is prior to the end of the Week $12$ window. **Excluded from PP.**\n-   $S_4$: Fails criterion (3). The exposure proportion is $E=0.76$, and $0.76  0.80$. **Excluded from PP.**\n-   $S_7$: Fails criterion (4). The Week $12$ biomarker measurement was not observed. **Excluded from PP.**\n-   $S_8$: Meets all criteria. (1) No major deviation. (2) No rescue. (3) $E=0.81$, and $0.81 \\geq 0.80$. (4) Week $12$ observed. **Included in PP.**\n-   $S_9$: Meets all criteria. (1) No major deviation. (2) No rescue. (3) $E=1.00$, and $1.00 \\geq 0.80$. (4) Week $12$ observed. **Included in PP.**\n-   $S_{10}$: Fails criterion (3). The exposure proportion is $E=0.79$, and $0.79  0.80$. **Excluded from PP.**\n-   $S_{11}$: Meets all criteria. (1) No major deviation. (2) No rescue. (3) $E=0.90$, and $0.90 \\geq 0.80$. (4) Week $12$ observed. **Included in PP.**\n-   $S_{12}$: Meets all criteria. (1) No major deviation. (2) No rescue. (3) $E=0.86$, and $0.86 \\geq 0.80$. (4) Week $12$ observed. **Included in PP.**\n-   $S_{13}$: Fails criterion (2). The subject used rescue medication at Week $11$, which is prior to the end of the Week $12$ window. **Excluded from PP.**\n-   $S_{14}$: Fails criterion (1). The subject had a major deviation. **Excluded from PP.**\n\n**Step 3: Count the Subjects in the PP Population**\n\nBy applying the specific exclusion rules to the mITT population, we find that the following subjects are included in the per-protocol population: $S_1$, $S_8$, $S_9$, $S_{11}$, and $S_{12}$.\n\nCounting these subjects gives the total size of the PP population.\nNumber of subjects in PP population = $5$.", "answer": "$$\\boxed{5}$$", "id": "5063608"}, {"introduction": "Raw data collected during a trial, such as biomarker measurements, are seldom ready for immediate statistical analysis. An SAP must provide an unambiguous, step-by-step algorithm for transforming this raw data into a clean, analysis-ready variable. This practice problem [@problem_id:5063621] challenges you to execute such an algorithm, involving data cleaning, outlier handling, and visit windowing, to derive a single endpoint value for a participant.", "problem": "In a Phase I translational medicine study, a prespecified Statistical Analysis Plan (SAP) defines how a continuous biomarker (measured in mg/dL) is to be cleaned, windowed to visits, and transformed into the analysis-ready variable. You are to compute the primary analysis variable for a single participant: the change-from-baseline at nominal Week $12$. All steps must strictly follow the SAP-defined rules below. The final answer must be a single real number. Express the final change in mg/dL and round your answer to $4$ significant figures.\n\nPrespecified SAP rules:\n\n- Data cleaning and censoring:\n  1. Exclude any observation flagged as hemolyzed.\n  2. Exclude any observation flagged with instrument quality control failure.\n  3. Handle lower limit of quantification (LLOQ): if a value is reported below the LLOQ, replace it with $\\text{LLOQ}/2$. The LLOQ is $0.5$ mg/dL.\n- Physiological plausibility and outlier handling:\n  - Winsorize to the physiologically plausible range $[0.2, 80]$ mg/dL after applying the LLOQ rule. Any value below $0.2$ is set to $0.2$, and any value above $80$ is set to $80$.\n- Replicates on the same study day:\n  - After applying all cleaning and winsorization rules, if multiple replicates remain on the same study day, replace them with their arithmetic mean.\n- Visit windowing:\n  - Nominal baseline (Day $1$) has a window of Days $[-7, +1]$ relative to Day $1$.\n  - Nominal Week $12$ (Day $84$) has a window of Days $[77, 98]$.\n  - Within a visit window, if multiple distinct study days remain, select the measurement from the day whose absolute difference to the nominal day is smallest; if there is a tie, select the earlier day.\n- Definition of the analysis variable:\n  - Baseline is defined as the selected measurement within the baseline window.\n  - Week $12$ is defined as the selected measurement within the Week $12$ window.\n  - The analysis variable is the change-from-baseline at Week $12$, computed as Week $12$ value minus baseline value.\n\nYou are provided the following laboratory records for this participant (study day is relative to Day $1$):\n\n- Study day $0$, value $13.0$, flag: instrument quality control fail.\n- Study day $1$, value $11.8$, replicate identifier: a, no flags.\n- Study day $1$, value $12.2$, replicate identifier: b, no flags.\n- Study day $84$, value $79.0$, flag: hemolyzed.\n- Study day $86$, value $120.0$, replicate identifier: a, no flags.\n- Study day $86$, value $82.0$, replicate identifier: b, no flags.\n\nCompute the change-from-baseline at nominal Week $12$ (Week $12$ value minus baseline value) according to the SAP rules above. Express your final answer in mg/dL and round to $4$ significant figures.", "solution": "The problem requires us to apply the Statistical Analysis Plan (SAP) rules in the specified order to derive the analysis variable.\n\nThe initial dataset for the participant is:\n\\begin{itemize}\n    \\item Study day $0$, value $13.0$ mg/dL, flag: instrument quality control fail.\n    \\item Study day $1$, value $11.8$ mg/dL, replicate identifier: a, no flags.\n    \\item Study day $1$, value $12.2$ mg/dL, replicate identifier: b, no flags.\n    \\item Study day $84$, value $79.0$ mg/dL, flag: hemolyzed.\n    \\item Study day $86$, value $120.0$ mg/dL, replicate identifier: a, no flags.\n    \\item Study day $86$, value $82.0$ mg/dL, replicate identifier: b, no flags.\n\\end{itemize}\n\n**Step 1: Data Cleaning and Censoring**\n\nFirst, I apply the rules for data exclusion and handling values below the lower limit of quantification (LLOQ).\n\n1.  **Exclude hemolyzed samples:** The observation on study day $84$ (value $79.0$ mg/dL) is flagged as hemolyzed and must be excluded.\n2.  **Exclude instrument quality control failures:** The observation on study day $0$ (value $13.0$ mg/dL) has an instrument quality control failure flag and must be excluded.\n3.  **Handle LLOQ:** The LLOQ is specified as $0.5$ mg/dL. Values below this limit are to be replaced by $\\text{LLOQ}/2 = 0.5/2 = 0.25$ mg/dL. The remaining raw values are $11.8$, $12.2$, $120.0$, and $82.0$ mg/dL. None of these values are below the LLOQ of $0.5$ mg/dL, so this rule results in no changes to the data.\n\nAfter the cleaning step, the dataset is reduced to:\n\\begin{itemize}\n    \\item Study day $1$, value $11.8$ mg/dL, replicate a.\n    \\item Study day $1$, value $12.2$ mg/dL, replicate b.\n    \\item Study day $86$, value $120.0$ mg/dL, replicate a.\n    \\item Study day $86$, value $82.0$ mg/dL, replicate b.\n\\end{itemize}\n\n**Step 2: Physiological Plausibility and Outlier Handling (Winsorization)**\n\nThe SAP states that values must be Winsorized to the physiologically plausible range of $[0.2, 80]$ mg/dL. This is applied after the LLOQ rule. Any value below $0.2$ is set to $0.2$, and any value above $80$ is set to $80$.\n\nApplying this to the cleaned data:\n\\begin{itemize}\n    \\item Day $1$, value $11.8$: This is within the range $[0.2, 80]$, so it remains $11.8$.\n    \\item Day $1$, value $12.2$: This is within the range $[0.2, 80]$, so it remains $12.2$.\n    \\item Day $86$, value $120.0$: This is above $80$, so it is Winsorized to $80.0$.\n    \\item Day $86$, value $82.0$: This is above $80$, so it is Winsorized to $80.0$.\n\\end{itemize}\n\nThe dataset after Winsorization is:\n\\begin{itemize}\n    \\item Study day $1$, value $11.8$ mg/dL.\n    \\item Study day $1$, value $12.2$ mg/dL.\n    \\item Study day $86$, value $80.0$ mg/dL.\n    \\item Study day $86$, value $80.0$ mg/dL.\n\\end{itemize}\n\n**Step 3: Handling of Replicates**\n\nThe SAP rule is to replace multiple replicates on the same study day with their arithmetic mean.\n\n\\begin{itemize}\n    \\item For study day $1$, the mean of the replicates is $\\frac{11.8 + 12.2}{2} = \\frac{24.0}{2} = 12.0$ mg/dL.\n    \\item For study day $86$, the mean of the replicates is $\\frac{80.0 + 80.0}{2} = \\frac{160.0}{2} = 80.0$ mg/dL.\n\\end{itemize}\n\nAfter this step, we have one value per study day. The processed analysis-ready dataset is:\n\\begin{itemize}\n    \\item Study day $1$: value $12.0$ mg/dL.\n    \\item Study day $86$: value $80.0$ mg/dL.\n\\end{itemize}\n\n**Step 4: Visit Windowing**\n\nNext, I select the definitive value for the baseline and Week $12$ visits using the windowing rules.\n\n\\begin{itemize}\n    \\item **Baseline Visit:**\n        \\begin{itemize}\n            \\item Nominal day: Day $1$.\n            \\item Window: Days $[-7, +1]$.\n            \\item The only available data point in our processed dataset that falls within this window is the measurement on day $1$.\n            \\item Therefore, the baseline value is $12.0$ mg/dL.\n        \\end{itemize}\n    \\item **Week $12$ Visit:**\n        \\begin{itemize}\n            \\item Nominal day: Week $12$ corresponds to day $12 \\times 7 = 84$. So, nominal day is Day $84$.\n            \\item Window: Days $[77, 98]$.\n            \\item The only available data point in our processed dataset that falls within this window is the measurement on day $86$.\n            \\item Per the selection rule, we select this single available day. The tie-breaking rules are not needed.\n            \\item Therefore, the Week $12$ value is $80.0$ mg/dL.\n        \\end{itemize}\n\\end{itemize}\n\n**Step 5: Calculation of the Analysis Variable**\n\nThe primary analysis variable is the change-from-baseline at Week $12$, calculated as the Week $12$ value minus the baseline value.\n\n\\begin{itemize}\n    \\item Baseline Value: $12.0$ mg/dL.\n    \\item Week $12$ Value: $80.0$ mg/dL.\n    \\item Change-from-baseline = $80.0 - 12.0 = 68.0$ mg/dL.\n\\end{itemize}\n\n**Step 6: Final Answer Formatting**\n\nThe problem requires the final answer to be rounded to $4$ significant figures. The calculated result is $68.0$, which has three significant figures. To express this value with four significant figures, it must be written as $68.00$.", "answer": "$$\\boxed{68.00}$$", "id": "5063621"}, {"introduction": "When a study tests multiple hypotheses, the probability of finding a 'significant' result by chance alone (a Type I error) increases. A rigorous SAP addresses this by prespecifying a statistical procedure to control for this multiplicity, ensuring the overall credibility of the findings. In this exercise [@problem_id:5063622], you will apply two common methods for controlling the Family-Wise Error Rate to a set of $p$-values, demonstrating how these adjustments maintain statistical integrity when making confirmatory claims.", "problem": "A translational medicine platform study evaluates whether a novel small-molecule modulates a predefined set of pathway-linked biomarkers measured in the same cohort. The Statistical Analysis Plan (SAP) prespecifies control of the Family-Wise Error Rate (FWER) at level $\\alpha = 0.05$ for $m = 8$ two-sided null hypotheses, with both the Holm step-down and the Hochberg step-up multiplicity adjustments executed as co-primary procedures under the assumption that the biomarker-level $p$-values are mutually independent. Independence is justified by orthogonal assay designs and pre-specified residualization that removes shared covariate effects. The observed $p$-values for the hypotheses $\\{H_{1},\\dots,H_{8}\\}$ are as follows: $H_{1}: 0.0123$, $H_{2}: 0.0049$, $H_{3}: 0.0270$, $H_{4}: 0.0008$, $H_{5}: 0.0190$, $H_{6}: 0.2100$, $H_{7}: 0.0115$, $H_{8}: 0.0079$. Starting from first principles of Family-Wise Error Rate control and without invoking any unproven shortcuts, apply the Holm and Hochberg procedures to these $p$-values to determine the number of rejected null hypotheses under each procedure at level $\\alpha = 0.05$. Report as your final answer a single integer equal to the increase in the count of rejected hypotheses under Hochberg relative to Holm. No rounding is needed. Express the final answer as a pure number without any units.", "solution": "The primary objective is to control the Family-Wise Error Rate (FWER) at $\\alpha = 0.05$ for $m=8$ hypotheses. The first step for both the Holm and Hochberg procedures is to order the $p$-values from smallest to largest.\n\nThe observed $p$-values are: $0.0123, 0.0049, 0.0270, 0.0008, 0.0190, 0.2100, 0.0115, 0.0079$.\n\nOrdering these gives the ordered $p$-values $p_{(j)}$ and their corresponding hypotheses $H_{(j)}$:\n$p_{(1)} = 0.0008$ (for $H_{4}$)\n$p_{(2)} = 0.0049$ (for $H_{2}$)\n$p_{(3)} = 0.0079$ (for $H_{8}$)\n$p_{(4)} = 0.0115$ (for $H_{7}$)\n$p_{(5)} = 0.0123$ (for $H_{1}$)\n$p_{(6)} = 0.0190$ (for $H_{5}$)\n$p_{(7)} = 0.0270$ (for $H_{3}$)\n$p_{(8)} = 0.2100$ (for $H_{6}$)\n\n**Holm Step-Down Procedure**\nThe Holm procedure compares each ordered $p$-value $p_{(j)}$ to an adjusted significance threshold $\\frac{\\alpha}{m - j + 1}$, starting from $j=1$. We stop at the first comparison that fails.\n\n1.  For $j=1$: Compare $p_{(1)} = 0.0008$ with $\\frac{0.05}{8} = 0.00625$. Since $0.0008 \\le 0.00625$, reject $H_{(1)}$ and proceed.\n2.  For $j=2$: Compare $p_{(2)} = 0.0049$ with $\\frac{0.05}{7} \\approx 0.00714$. Since $0.0049 \\le 0.00714$, reject $H_{(2)}$ and proceed.\n3.  For $j=3$: Compare $p_{(3)} = 0.0079$ with $\\frac{0.05}{6} \\approx 0.00833$. Since $0.0079 \\le 0.00833$, reject $H_{(3)}$ and proceed.\n4.  For $j=4$: Compare $p_{(4)} = 0.0115$ with $\\frac{0.05}{5} = 0.01$. Since $0.0115 > 0.01$, the condition is not met. The procedure stops.\n\nWe reject hypotheses $H_{(1)}, H_{(2)},$ and $H_{(3)}$. The remaining hypotheses are not rejected.\nThe number of rejected hypotheses under the Holm procedure is $N_{Holm} = 3$.\n\n**Hochberg Step-Up Procedure**\nThe Hochberg procedure is more powerful and requires the assumption of independence (which is given). The algorithm finds the largest index $k$ such that $p_{(k)} \\le \\frac{\\alpha}{m - k + 1}$. If such a $k$ exists, all hypotheses $H_{(1)}, \\dots, H_{(k)}$ are rejected. We check this condition starting from the largest $p$-value ($j=m$) and working backwards.\n\n1.  For $j=8$: Compare $p_{(8)} = 0.2100$ with $\\frac{0.05}{1} = 0.05$. The condition $p_{(8)} \\le 0.05$ is not met ($0.2100 > 0.05$).\n2.  For $j=7$: Compare $p_{(7)} = 0.0270$ with $\\frac{0.05}{2} = 0.025$. The condition $p_{(7)} \\le 0.025$ is not met ($0.0270 > 0.025$).\n3.  For $j=6$: Compare $p_{(6)} = 0.0190$ with $\\frac{0.05}{3} \\approx 0.01667$. The condition $p_{(6)} \\le 0.01667$ is not met ($0.0190 > 0.01667$).\n4.  For $j=5$: Compare $p_{(5)} = 0.0123$ with $\\frac{0.05}{4} = 0.0125$. The condition $p_{(5)} \\le 0.0125$ is met ($0.0123 \\le 0.0125$).\n\nThe largest index $k$ that satisfies the condition is $k=5$. Therefore, we reject all hypotheses $H_{(j)}$ for $j=1, \\dots, 5$.\nThe number of rejected hypotheses under the Hochberg procedure is $N_{Hochberg} = 5$.\n\n**Final Calculation**\nThe problem asks for the increase in the number of rejected hypotheses under the Hochberg procedure relative to the Holm procedure.\nIncrease = $N_{Hochberg} - N_{Holm} = 5 - 3 = 2$.", "answer": "$$\\boxed{2}$$", "id": "5063622"}]}